Dr. Maxwell Sauder
Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Dana-Farber Cancer Institute. He is a former instructor in dermatology at Dana-Farber and Brigham and Women's Hospital.
Dr. Sauder is currently an assistant professor and the onco-dermatology fellowship director at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.
MAY 15 Fri
Optimizing Melanoma Care: Dermatologists’ Role in Risk Identification, Referral, and Ongoing Management
Learning Objectives:
- Apply key clinical and pathologic features to risk-stratify melanoma patients and guide timely staging and risk stratification
- Summarize indications, benefits, and safety considerations of immunotherapy across melanoma stages
- Promote active dermatology involvement in diagnosis, management, evaluation of clinical response and cutaneous toxicity
MAY 16 Sat
Molecular Maintenance: The Role of Ceramides in Barrier Normalization from AD Flare to Remission
While clinical clearance is the primary goal of AD therapy, molecular dysregulation often persists in non-lesional skin. This session explores the role of IL-1α as a critical stress-induced alarmin that drives subclinical inflammation during remission. We will analyze how ceramide-dominant therapies can quiet this "molecular alarm," normalizing the skin barrier and raising the threshold for future clinical flares.
Learning Objectives:
- Analyze current guidelines to define the foundational role of therapeutic skincare as both monotherapy and adjunctive to systemic treatments in atopic dermatitis
- Examine the pathophysiology of subclinical inflammation in non-lesional skin, specifically the role of IL-1α as a stress-induced 'alarmin' and a primary driver of barrier-defect persistence
- Evaluate the role of ceramide-based therapies in normalizing skin-barrier deficiencies during AD flare ups and remission phases
